We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

DNASTAR Awarded Antibody Engineering SBIR Grant

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

DNASTAR® has announced that it has received a Phase I SBIR grant award from the National Institutes of Health entitled, “Structural bioinformatics software for epitope selection and antibody engineering”.

The funding will support the company’s research and development aimed at producing a superior antibody engineering capability on a desktop computer.

It is also a key step in the direction of producing a comprehensive desktop proteomics software suite, which is well underway at DNASTAR.

Tom Schwei, Vice President and General Manager of DNASTAR, commented, “When most life scientists think about DNASTAR today, they focus on the “DNA” aspect of our products and company name. This is very appropriate as we have established a strong reputation for producing high quality, easy to use desktop genomics software. However, there is much more to DNASTAR than simply genomics.

“For the past several years, we have been building a foundation for our emerging proteomics platform in Protean 3D within our Lasergene software suite. This grant project will help us move quickly to develop a key component of our vision for our proteomics suite - creating a tool to produce superior epitope prediction and antibody engineering results compared to today’s available methods and tools.

“Long-term, we plan to continue developing our desktop computer proteomics suite to include protein structure prediction, protein motion, molecular interactions, and much more. We believe there is a great need for easy to use yet powerful desktop software to support scientists in the proteomics realm, much as we’ve been doing for scientists involved in genomics research for more than 25 years.”